Our Company
OzStar Therapeutics manufactured OZ101 tablets (a tableted form of Agulcator®) and used in a phase 2 clinical trial.
At A Glance
Scientifically Sound and Clinically Tested Technology
Agulcator® has gone through over a decade of rigorous scientific and clinical research and development to provide world-class alternative options to stabilise some aspects of diabetes in people with diabetes on sulphonylures. OzStar Therapeutic is at the forefront of microbiome science spearheading the prebiotic field for type 2 diabetics, with utilities for many other indications to follow. Our technology is backed up by emerging scientific publications and expert opinions of key opinion leaders.
Our Company
Company with a Strong Building Blocks.
The research and development conducted by OzStar Therapeutics has gone through a careful design and implementation to achieve desired excellence.
We are committed to providing best-in-class products to assist people with type 2 diabetes on sulphonylureas to stabilise their condition.
Dr. Nick N Gorgani, BE, MBBS, MS Drug Dev, Phd
Founder, president and CEO of OzStar Therapeutics
Therapeutic Areas of Focus
Diabetes Mellitus
Due to progressive and the pandemic nature of diabetes, currently available interventions for type 2 diabetes are inadequate and often accompany major side effects. We have focused on providing an alternative to combat type 2 diabetes through balancing gut microbiome dynamics.
Awards & Recognition
Our Technoology has been selected as a finalist by CONNECT's Most Innovative New Product Award 2016 in San Diego, CA, USA (Featured at 1:02-1:06 minutes).
Australian Government Grant
2013
Australian Government Grant
2014
MIP Finalist Badge
2016
MIP Finalsit Trophy
2016
Market Research Award
Our scientific advisory board member Professor Tulay Gerard, PhD, and her team from Pensylvania State University have received best market research award, after completing and presenting an excellently designed market research project on Agulcator®.
